About Opgen
OpGen: Revolutionizing Molecular Microbiology Solutions
OpGen is a leading molecular diagnostics company that specializes in developing and commercializing innovative solutions for the detection, diagnosis, and treatment of infectious diseases. The company's mission is to provide accurate, reliable, and cost-effective diagnostic tools that enable healthcare professionals to make informed decisions about patient care.
Founded in 2002, OpGen has since established itself as a pioneer in the field of molecular microbiology. The company's proprietary technology platform combines advanced genomics with bioinformatics to deliver rapid and accurate results for a wide range of infectious diseases.
OpGen's subsidiaries include Curetis AG and Ares Genetics GmbH. Curetis is a leading developer of next-generation sequencing (NGS) technology for the diagnosis of severe infections such as sepsis. Ares Genetics focuses on developing innovative solutions for antibiotic resistance testing using AI-powered bioinformatics.
The company's flagship product is the Acuitas® AMR Gene Panel u5.47, which enables rapid identification of antibiotic-resistant pathogens from clinical samples. This groundbreaking solution helps healthcare providers make informed decisions about appropriate antibiotic therapy while reducing the risk of antimicrobial resistance.
OpGen also offers other products such as Acuitas Lighthouse®, an infection control surveillance system that uses NGS technology to track outbreaks in real-time; QuickFISH®, a rapid diagnostic test for identifying pathogens directly from clinical specimens; and PNA FISH®, an FDA-cleared diagnostic test used to identify bloodstream infections caused by gram-positive bacteria.
In addition to its innovative product portfolio, OpGen has also established partnerships with leading academic institutions and research organizations worldwide. These collaborations have enabled the company to expand its knowledge base and develop new technologies that address unmet needs in molecular microbiology.
One example is OpGen's collaboration with New York University Langone Health (NYULH) on developing a novel NGS-based assay for detecting SARS-CoV-2 virus mutations associated with drug resistance or immune evasion. This partnership aims to improve COVID-19 patient outcomes by providing more accurate information about viral variants that may impact treatment efficacy.
Another notable collaboration is OpGen's partnership with Merck KGaA on developing new antibiotics targeting multidrug-resistant bacteria. This joint effort combines Merck KGaA's expertise in drug discovery with OpGen's advanced genomics capabilities to accelerate the development of novel therapeutics against antibiotic-resistant infections.
Overall, OpGen continues to lead innovation in molecular microbiology solutions through its cutting-edge technologies, strategic partnerships, and commitment to improving patient outcomes worldwide. With its focus on addressing unmet needs in infectious disease diagnostics and treatment, this pioneering company remains at the forefront of revolutionizing healthcare delivery globally.